Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2605502 | 0.78 | HTT (0.38) | PIK3CGIDH1 | |
| SCHEMBL19773453 | 0.75 | — | — | |
| SCHEMBL20049385 | 0.75 | PIK3CG (0.34) | PIK3CGIDH1 | |
| SCHEMBL9449998 | 0.75 | PIK3CG (0.34) | PIK3CGIDH1 | |
| SCHEMBL10147793 | 0.75 | PIK3CG (0.34) | PIK3CGIDH1 | |
| SCHEMBL21180509 | 0.72 | PIK3CG (0.35) | PIK3CGIDH1 | |
| SCHEMBL14213299 | 0.72 | PIK3CG (0.33) | PIK3CGIDH1 | |
| SCHEMBL22352951 | 0.71 | — | — | |
| SCHEMBL5170535 | 0.67 | HTT (0.36) | — | |
| SCHEMBL5388859 | 0.67 | PIK3CG (0.33) | PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018067704-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20160016952-A1 | SUBSTITUTED AMINO-PYRIMIDINE DERIVATIVES | ASANA BIOSCIENCES, LLC (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016952-A1 | SUBSTITUTED AMINO-PYRIMIDINE DERIVATIVES | MTOR, PIK3CA, AKT3 | PIK3CG 21/4885IDH1 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.